The Boulder, Colorado MP-12 Phase 2 Clinical Trial of the safety and efficacy of MDMA-Assisted Psychotherapy for people with chronic treatment resistant PTSD will be completed by the December 2015. Preliminary results demonstrate 80% of the study participants no longer meet criteria for chronic treatment resistant PTSD with an average reduction in their CAPS of 49 points (53% reduction – see below). Of the 20% who still meet criteria demonstrate significant improvements in quality of life and reduction of PTSD symptoms. Treatment occurs over 3 and a half months (5 months for our control group) and MDMA is administered 3 times (5 for control) during that time. We use the CAPS (Clinician-Administered PTSD Scale), which is the gold standard for PTSD assessment as well as a battery of other tests (including but not limited to PDS, BDI-II, CSSRS, GAF, RRPQ, SCID, PASAT, RBANS, etc). All sessions are video recorded and rated by independent parties for adherence to our treatment protocol. This study is one of 5 worldwide and the second largest to date. Based on research to date, this is one of the most promising approaches for decreasing the suffering while increasing the quality of life for people with PTSD.